Literature DB >> 18344980

Tumour maintenance is mediated by eNOS.

Kian-Huat Lim1, Brooke B Ancrile, David F Kashatus, Christopher M Counter.   

Abstract

Tumour cells become addicted to the expression of initiating oncogenes like Ras, such that loss of oncogene expression in established tumours leads to tumour regression. HRas, NRas or KRas are mutated to remain in the active GTP-bound oncogenic state in many cancers. Although Ras activates several proteins to initiate human tumour growth, only PI3K, through activation of protein kinase B (PKB; also known as AKT), must remain activated by oncogenic Ras to maintain this growth. Here we show that blocking phosphorylation of the AKT substrate, endothelial nitric oxide synthase (eNOS or NOS3), inhibits tumour initiation and maintenance. Moreover, eNOS enhances the nitrosylation and activation of endogenous wild-type Ras proteins, which are required throughout tumorigenesis. We suggest that activation of the PI3K-AKT-eNOS-(wild-type) Ras pathway by oncogenic Ras in cancer cells is required to initiate and maintain tumour growth.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18344980      PMCID: PMC2688829          DOI: 10.1038/nature06778

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  36 in total

1.  Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor.

Authors:  A Brunet; A Bonni; M J Zigmond; M Z Lin; P Juo; L S Hu; M J Anderson; K C Arden; J Blenis; M E Greenberg
Journal:  Cell       Date:  1999-03-19       Impact factor: 41.582

2.  Ha-ras and N-ras regulate MAPK activity by distinct mechanisms in vivo.

Authors:  M Hamilton; A Wolfman
Journal:  Oncogene       Date:  1998-03       Impact factor: 9.867

3.  Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes.

Authors:  K Kita; S Saito; C Y Morioka; A Watanabe
Journal:  Int J Cancer       Date:  1999-02-09       Impact factor: 7.396

4.  Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development.

Authors:  L M Esteban; C Vicario-Abejón; P Fernández-Salguero; A Fernández-Medarde; N Swaminathan; K Yienger; E Lopez; M Malumbres; R McKay; J M Ward; A Pellicer; E Santos
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

Review 5.  Cellular transformation by SV40 large T antigen: interaction with host proteins.

Authors:  S H Ali; J A DeCaprio
Journal:  Semin Cancer Biol       Date:  2001-02       Impact factor: 15.707

6.  Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation.

Authors:  S Dimmeler; I Fleming; B Fisslthaler; C Hermann; R Busse; A M Zeiher
Journal:  Nature       Date:  1999-06-10       Impact factor: 49.962

7.  Regulation of endothelium-derived nitric oxide production by the protein kinase Akt.

Authors:  D Fulton; J P Gratton; T J McCabe; J Fontana; Y Fujio; K Walsh; T F Franke; A Papapetropoulos; W C Sessa
Journal:  Nature       Date:  1999-06-10       Impact factor: 49.962

8.  LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer.

Authors:  Jie Li; Zhongqiu Zhang; Zunyan Dai; Christoph Plass; Carl Morrison; Yian Wang; Jonathan S Wiest; Marshall W Anderson; Ming You
Journal:  Oncogene       Date:  2003-02-27       Impact factor: 9.867

9.  Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway.

Authors:  Brendan D Manning; Andrew R Tee; M Nicole Logsdon; John Blenis; Lewis C Cantley
Journal:  Mol Cell       Date:  2002-07       Impact factor: 17.970

Review 10.  Targeting RAS signalling pathways in cancer therapy.

Authors:  Julian Downward
Journal:  Nat Rev Cancer       Date:  2003-01       Impact factor: 60.716

View more
  143 in total

1.  Dynamic denitrosylation via S-nitrosoglutathione reductase regulates cardiovascular function.

Authors:  Farideh Beigi; Daniel R Gonzalez; Khalid M Minhas; Qi-An Sun; Matthew W Foster; Shakil A Khan; Adriana V Treuer; Raul A Dulce; Robert W Harrison; Roberto M Saraiva; Courtney Premer; Ivonne Hernandez Schulman; Jonathan S Stamler; Joshua M Hare
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-24       Impact factor: 11.205

Review 2.  Redox regulation of Ras and Rho GTPases: mechanism and function.

Authors:  Lauren Mitchell; G Aaron Hobbs; Amir Aghajanian; Sharon L Campbell
Journal:  Antioxid Redox Signal       Date:  2012-07-30       Impact factor: 8.401

3.  Regulation of RAS oncogenicity by acetylation.

Authors:  Moon Hee Yang; Seth Nickerson; Eric T Kim; Caroline Liot; Gaelle Laurent; Robert Spang; Mark R Philips; Yibing Shan; David E Shaw; Dafna Bar-Sagi; Marcia C Haigis; Kevin M Haigis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-18       Impact factor: 11.205

Review 4.  Cardiovascular redox and ox stress proteomics.

Authors:  Vikas Kumar; Timothy Dean Calamaras; Dagmar Haeussler; Wilson Steven Colucci; Richard Alan Cohen; Mark Errol McComb; David Pimentel; Markus Michael Bachschmid
Journal:  Antioxid Redox Signal       Date:  2012-08-10       Impact factor: 8.401

Review 5.  How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.

Authors:  Ethan J Brock; Kyungmin Ji; John J Reiners; Raymond R Mattingly
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

6.  The Role of Nitric Oxide Synthase Uncoupling in Tumor Progression.

Authors:  Christopher S Rabender; Asim Alam; Gobalakrishnan Sundaresan; Robert J Cardnell; Vasily A Yakovlev; Nitai D Mukhopadhyay; Paul Graves; Jamal Zweit; Ross B Mikkelsen
Journal:  Mol Cancer Res       Date:  2015-02-27       Impact factor: 5.852

Review 7.  Posttranslational Modifications of RAS Proteins.

Authors:  Ian Ahearn; Mo Zhou; Mark R Philips
Journal:  Cold Spring Harb Perspect Med       Date:  2018-11-01       Impact factor: 6.915

8.  Low dose radiation primed iNOS + M1macrophages modulate angiogenic programming of tumor derived endothelium.

Authors:  Vinod Nadella; Sandhya Singh; Aklank Jain; Manju Jain; Karen M Vasquez; Ashok Sharma; Pranay Tanwar; Goura Kishore Rath; Hridayesh Prakash
Journal:  Mol Carcinog       Date:  2018-08-10       Impact factor: 4.784

9.  Wild-type RAS: keeping mutant RAS in CHK.

Authors:  Theonie Anastassiadis; Eric J Brown
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

10.  Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.

Authors:  Elda Grabocka; Yuliya Pylayeva-Gupta; Mathew J K Jones; Veronica Lubkov; Eyoel Yemanaberhan; Laura Taylor; Hao Hsuan Jeng; Dafna Bar-Sagi
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.